title: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers.
abstract: The molecular basis for the beneficial impact of essential omega-3 (n-3) FA remains of interest. Recently, we identified novel mediators generated from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that displayed potent bioactions identified first in resolving inflammatory exudates and in tissues enriched with DHA. The trivial names resolvin (resolution phase interaction products) and docosatrienes were introduced for the bioactive compounds from these novel series since they possess potent anti-inflammatory and immunoregulatory actions. Compounds derived from EPA carrying potent biological actions (i.e., 1-10 nM range) are designated E series and denoted resolvins of the E series (resolvin E1 or RvE1), and those biosynthesized from the precursor DHA are denoted resolvins of the D series (resolvin D1 or RvD1). The number 1 designates the bioactive compounds in this family (#1-4). Bioactive members from DHA-containing conjugated triene structures or docosatrienes (DT) that possess immunoregulatory and neuroprotective actions were termed neuroprotectins. Aspirin treatment initiates a related epimeric series by triggering endogenous formation of the 17R-D series resolvins and docosatrienes. These epimers are denoted as aspirin-triggered (AT)-RvD and DT, and possess potent anti-inflammatory actions in vivo essentially equivalent to their 17S series pathway products. These include five distinct series: (i) 18R resolvins from EPA (i.e., RvE1); (ii) 17R series (AT) resolvins from DHA (RvD1 through RvD4); (iii) 17S series resolvins from DHA (RvD1 through RvD4), (iv) DT from DHA; and (v) their AT form 17R series DT. In this article, we provide an overview of the formation and actions of these newly uncovered pathways and products.
authors.affiliation: Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. cnserhan@zeus.bwh.harvard.edu
authors.forename: Charles N
authors.initials: CN
authors.lastname: Serhan
authors.forename: Makoto
authors.initials: M
authors.lastname: Arita
authors.forename: Song
authors.initials: S
authors.lastname: Hong
authors.forename: Katherine
authors.initials: K
authors.lastname: Gotlinger
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D004281:Docosahexaenoic Acids / Q000737:chemistry / Q000378:metabolism*; D015118:Eicosapentaenoic Acid / Q000737:chemistry / Q000378:metabolism*; D015525:Fatty Acids, Omega-3 / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D018696:Neuroprotective Agents / Q000737:chemistry* / Q000378:metabolism
chemical_list: D015525:Fatty Acids, Omega-3; D018696:Neuroprotective Agents; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; D001241:Aspirin
references.citation: Nutr Rev. 1973 Aug;31(8):248-9
references.pmid: 4586201
references.citation: Lipids. 2001 Sep;36(9):945-59
references.pmid: 11724467
references.citation: Biochemistry. 2000 Mar 7;39(9):2376-83
references.pmid: 10694406
references.citation: FASEB J. 2003 Apr;17(6):652-9
references.pmid: 12665478
references.citation: J Biol Chem. 2003 Oct 31;278(44):43807-17
references.pmid: 12923200
references.citation: Science. 2002 Apr 19;296(5567):474-5
references.pmid: 11964462
references.citation: J Clin Invest. 1984 Dec;74(6):1922-33
references.pmid: 6096400
references.citation: Nature. 2003 Jul 3;424(6944):88-93
references.pmid: 12840763
references.citation: Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15579-84
references.pmid: 15496467
references.citation: Lab Invest. 1994 Sep;71(3):380-6
references.pmid: 7523762
references.citation: Circulation. 2002 Apr 23;105(16):1897-903
references.pmid: 11997274
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8491-6
references.pmid: 15152078
references.citation: J Clin Invest. 1990 Mar;85(3):772-80
references.pmid: 2155925
references.citation: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:211-34
references.pmid: 12432920
references.citation: N Engl J Med. 1980 Jul 3;303(1):27-34
references.pmid: 6246431
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2003 Mar;68(3):213-8
references.pmid: 12591005
references.citation: JAMA. 2004 Feb 4;291(5):585-90
references.pmid: 14762037
references.citation: Nat Med. 2002 Nov;8(11):1296-302
references.pmid: 12368905
references.citation: Mol Pharmacol. 2003 Sep;64(3):721-30
references.pmid: 12920210
references.citation: J Pharmacol Exp Ther. 2002 Feb;300(2):385-92
references.pmid: 11805195
references.citation: JAMA. 2004 Feb 4;291(5):623-4
references.pmid: 14762043
references.citation: Proc Natl Acad Sci U S A. 1984 Sep;81(17):5335-9
references.pmid: 6089195
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2135-9
references.pmid: 14766977
references.citation: J Dent Res. 2003 Feb;82(2):82-90
references.pmid: 12562878
references.citation: J Clin Invest. 2001 Jun;107(12):1481-9
references.pmid: 11413151
references.citation: J Exp Med. 2005 Mar 7;201(5):713-22
references.pmid: 15753205
references.citation: Biochemistry. 1994 Feb 1;33(4):856-63
references.pmid: 8305432
references.citation: Proc Natl Acad Sci U S A. 1983 Jun;80(12):3581-4
references.pmid: 6304720
references.citation: J Immunol. 2003 Dec 15;171(12):6856-65
references.pmid: 14662892
references.citation: J Neurochem. 1994 Jun;62(6):2437-47
references.pmid: 8189247
references.citation: Lancet. 1999 Aug 7;354(9177):447-55
references.pmid: 10465168
references.citation: Nat Genet. 2004 Mar;36(3):233-9
references.pmid: 14770184
references.citation: J Biol Chem. 2003 Apr 25;278(17):14677-87
references.pmid: 12590139
references.citation: J Immunol. 2000 Feb 15;164(4):1663-7
references.pmid: 10657608
references.citation: J Immunol. 2003 Mar 1;170(5):2688-94
references.pmid: 12594298
references.citation: Lipids. 2003 Apr;38(4):317-21
references.pmid: 12848276
references.citation: Kidney Int. 2003 Aug;64(2):480-92
references.pmid: 12846743
references.citation: J Biol Chem. 1992 Aug 15;267(23):16168-76
references.pmid: 1322894
references.citation: Science. 2002 Apr 19;296(5567):539-41
references.pmid: 11964481
references.citation: J Exp Med. 1996 Jan 1;183(1):137-46
references.pmid: 8551217
references.citation: J Am Coll Nutr. 1999 Oct;18(5):487-9
references.pmid: 10511332
references.citation: J Biol Chem. 1984 May 10;259(9):5776-83
references.pmid: 6232277
references.citation: J Biol Chem. 1996 Sep 13;271(37):22663-71
references.pmid: 8798438
references.citation: J Immunol. 2002 May 15;168(10):5260-7
references.pmid: 11994483
references.citation: J Exp Med. 2002 Oct 21;196(8):1025-37
references.pmid: 12391014
references.citation: FEBS Lett. 1999 Apr 16;449(1):7-11
references.pmid: 10225417
references.citation: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:303-12
references.pmid: 12432925
references.citation: J Exp Med. 2000 Oct 16;192(8):1197-204
references.pmid: 11034610
references.citation: Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:235-43
references.pmid: 12432921
references.citation: J Exp Med. 1994 Jul 1;180(1):253-60
references.pmid: 8006586
references.citation: Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9475-9
references.pmid: 7568157